Novartis and Sawai end Japan ciclosporin case
This article was originally published in Scrip
Novartisand the Japanese generics company Sawai have agreed to end litigation relating to the immunosuppressant ciclosporin. The Swiss firm instigated legal action against Sawai in the Tokyo district court in December 2006, claiming the company's generic ciclosporin capsules infringed patents for its original branded product Neoral. Without disclosing terms, Sawai said that the action had now been halted and that sales of its product would continue unaffected.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.